%0 Journal Article %T Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice %A Lin, Jianzhen %A Dong, Kun %A Bai, Yi %A Zhao, Songhui %A Dong, Yonghong %A Shi, Junping %A Shi, Weiwei %A Long, Junyu %A Yang, Xu %A Wang, Dongxu %A Yang, Xiaobo %A Zhao, Lin %A Hu, Ke %A Pan, Jie %A Sang, Xinting %A Wang, Kai %A Zhao, Haitao %J Annals of Translational Medicine %D 2019 %B 2019 %9 %! Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice %K %X Background: Gallbladder cancer (GBC) is an uncommon but highly fatal malignancy, with limited adjuvant therapy. The present study aims to explore the actionable alterations and precision oncology for GBC patients. Methods: Patients with pathologically confirmed GBC who progressed after first-line systemic treatment were enrolled. Genomic alterations were captured by ultra-deep targeted next-generation sequencing (tNGS). The actionabilities of alterations and the therapeutic regimens were evaluated by a multidisciplinary tumor board (MDTB). Results: Sixty patients with GBC were enrolled and analyzed. tNGS was successfully achieved in all patients. The median tumor mutation burden for GBC patients was 5.4 (range: 0.8–36.74) mutations/Mb, and the most common mutations were in TP53 (73%), CDKN2A (25%) and PIK3CA (20%). The most frequently copy-number altered genes were CDKN2A deletion (11.7%) and ERBB2 amplification (13.3%). 23% of the patients displayed gene fusion; 17 fusion events were identified, and 14 of the 17 fusion events co-occurred with mutations in driver genes. In total, 46 of the 60 (76%) patients were identified as possessing at least one actionable target to proceed precision oncology. Conclusions: The present study revealed the mutational profile for the clinical practice of precision oncology in GBC patients. %U https://atm.amegroups.org/article/view/29021 %V 7 %N 18 %P 467 %@ 2305-5847